ArticleDermatology and therapy2026
Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Sham-Controlled Trial.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06994819 (Double-blind Randomized Controlled Clinical Trial Under Dermatological Monitoring on Skin Tolerability and Efficacy of the Niostem Headset on Hair Growth, Hair Loss and Hair Quality After 3 and 6 Months of Daily Use), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind Randomized Controlled Clinical Trial Under Dermatological Monitoring on Skin Tolerability and Efficacy of the Niostem Headset on Hair Growth, Hair Loss and Hair Quality After 3 and 6 Months of Daily Use
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAndrogenetic alopecia (AGA), the most common form of hereditary hair loss, is highly prevalent and commonly requires long-term, consistent treatment. This randomized controlled trial evaluated the efficacy, safety, and tolerability of a wearable electrotrichogenic (ETG) device (niostem) compared with a sham device in men with AGA.
methodsThis single-center, randomized, double-blind, sham-controlled clinical trial enrolled 81 men (18-55 years of age; Norwood-Hamilton scale II-VI) assigned to the active ETG or sham group in a 5:3 ratio. Participants used the assigned device 30 min daily for 24 weeks. Efficacy was assessed in a prespecified per-protocol population (treatment compliance ≥ 70%). Outcomes were assessed at baseline, month 3, and month 6 using standardized global photography and trichoscopic analysis. The primary endpoint was the between-group difference in change from baseline to month 6 in total hair density (hairs/cm
resultsAt month 6, total hair density change was significantly greater in the active ETG group than in the sham group (mean difference 24.40 hairs/cm
conclusionDaily use of the niostem ETG wearable significantly improved total and terminal hair density and cumulative hair thickness compared to the sham treatment, with effects apparent at month 6.
trial registrationClinicalTrials.gov NCT06994819; registered 29 May 2025 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.